Abbott Laboratories (NYSE:ABT) is set to issue its quarterly earnings data before the market opens on Wednesday, January 23rd. Analysts expect the company to announce earnings of $0.81 per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Shares of Abbott Laboratories stock opened at $71.42 on Monday. The company has a current ratio of 1.42, a quick ratio of 1.13 and a debt-to-equity ratio of 0.62. Abbott Laboratories has a 52-week low of $55.58 and a 52-week high of $74.92. The company has a market capitalization of $125.44 billion, a PE ratio of 28.57, a PEG ratio of 1.91 and a beta of 1.24.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Stockholders of record on Tuesday, January 15th will be issued a $0.32 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.28. The ex-dividend date is Monday, January 14th. This represents a $1.28 annualized dividend and a dividend yield of 1.79%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 51.20%.
ABT has been the topic of several recent analyst reports. Wells Fargo & Co raised their target price on shares of Abbott Laboratories from $77.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, September 24th. Raymond James raised their target price on shares of Abbott Laboratories from $72.00 to $77.00 and gave the stock an “outperform” rating in a report on Monday, September 24th. Cowen raised their target price on shares of Abbott Laboratories from $72.00 to $86.00 and gave the stock an “average” rating in a report on Friday, October 5th. JPMorgan Chase & Co. raised their target price on shares of Abbott Laboratories from $77.00 to $81.00 and gave the stock an “overweight” rating in a report on Monday, October 8th. Finally, Zacks Investment Research lowered Abbott Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $76.86.
In related news, insider Jared Watkin sold 65,000 shares of the firm’s stock in a transaction on Friday, November 2nd. The stock was sold at an average price of $71.00, for a total value of $4,615,000.00. Following the completion of the sale, the insider now owns 128,640 shares of the company’s stock, valued at $9,133,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Miles D. White sold 142,341 shares of the firm’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $72.35, for a total value of $10,298,371.35. Following the completion of the sale, the chairman now directly owns 3,459,185 shares of the company’s stock, valued at approximately $250,272,034.75. The disclosure for this sale can be found here. Company insiders own 0.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2019/01/21/abbott-laboratories-abt-set-to-announce-earnings-on-wednesday.html.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
See Also: Is a Roth IRA right for you?
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.